AmberSight

AmberSight is a pre-clinical stage biotechnology company dedicated to developing transformative gene therapies for patients with inherited retinal diseases. Founded by Dr. Jean Bennett, a pioneer in ocular gene therapy and co-developer of the first FDA-approved gene therapy Luxturna, the company leverages advanced viral vector technologies to address complex genetic causes of blindness. AmberSight's primary focus includes conditions such as Stargardt disease, where it utilizes innovative delivery methods to overcome the challenges of large gene payloads. Headquartered in Philadelphia, the company is positioned at the forefront of genomic medicine in ophthalmology. Its mission is to restore and preserve vision through precise, one-time genetic interventions.